This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
E Alvarez , V Perez , M Dragheim , H Loft , (2011). A double-blind, randomized, placebo-controlled, active reference study of vortioxetine in patients with major depressive disorder. International Journal of Neuropsychopharmacology 15, 589–600.
AK Ashton , BD Jamerson , W Weinstein , C Wagoner (2005). Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Current Therapeutic Research 66, 96–106.
B Bang-Andersen , T Ruhland , M Jorgensen , G Smith , (2011). Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (vortioxetine): a novel multimodal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry 54, 3206–3221.
JP Boulenger , H Loft , I Florea (2012). A randomized clinical study of vortioxetine in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology. Published online: 9 April 2012. doi:10.1177/0269881112441866.
JA Bridge , B Birmaher , S Iyengar , RP Barbe , (2009). Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. American Journal of Psychiatry 166, 42–49.
AR Brunoni , M Lopes , TJ Kaptchuk , F Fregni (2009). Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS ONE 4, e4824.
RA Hansen , G Gartlehner , KN Lohr , BN Gaynes , (2005). Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 143, 415–426.
DS Hasin , RD Goodwin , FS Stinson , BF Grant (2005). Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Archives of General Psychiatry 62, 1097–1106.
N Henigsberg , A Mahableshwarkar , P Jacobsen , Y Chen , (2011). P.2.c.018 Efficacy and tolerability of multiple doses of LU AA21004 in an 8-week trial of adults with major depressive disorder. European Neuropsychopharmacology 21 (Suppl. 3), S393.
XH Hu , SA Bull , EM Hunkeler , E Ming , (2004). Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report vs. physician estimate. Journal of Clinical Psychiatry 65, 959–965.
LL Judd , HS Akiskal , PJ Zeller , M Paulus , (2000). Psychosocial disability during the long-term course of unipolar major depressive disorder. Archives of General Psychiatry 57, 375–380.
W Katon , P Ciechanowski (2002). Impact of major depression on chronic medical illness. Journal of Psychosomatic Research 53, 859–863.
C Katona , T Hansen , CK Olsen . (2012). A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of vortioxetine in elderly patients with major depressive disorder. International Clinical Psychopharmacology 27, 215–223.
RC Kessler , P Berglund , O Demler , R Jin , (2003). The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). Journal of the American Medical Association 289, 3095–3105.
A Khan , A Bhat , R Kolts , ME Thase , (2010). Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neuroscience and Therapeutics 16, 217–226.
CH Mallinckrodt , RN Tamura , Y Tanaka (2011). Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. Journal of Psychiatric Research 45, 1202–1207.
A Mork , A Pehrson , L Tottrup Brennum , S Moller Nielsen , (2011). Pharmacological effects of vortioxetine: a novel multimodal compound for the treatment of major depressive disorder. Journal of Pharmacology and Experimental Therapeutics 340, 666–675.
JC Mundt , JH Greist , JW Jefferson , DJ Katzelnick , (2007). Is it easier to find what you are looking for if you think you know what it looks like? Journal of Clinical Psychopharmacology 27, 121–125.
S Rosenzweig-Lipson , CE Beyer , ZA Hughes , X Khawaja , (2007). Differentiating antidepressants of the future: efficacy and safety. Pharmacology and Therapeutics 113, 134–153.
LE Schechter , RH Ring , CE Beyer , ZA Hughes , (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRX 2, 590–611.
S Stewart-Williams , J Podd (2004). The placebo effect: dissolving the expectancy vs. conditioning debate. Psychology Bulletin 130, 324–340.
D Warden , A Rush , M Trivedi , M Fava , (2007). The STAR*D project results: a comprehensive review of findings. Current Psychiatry Reports 9, 449–459.
C Zlotnick , R Kohn , G Keitner , SA Della Grotta (2000). The relationship between quality of interpersonal relationships and major depressive disorder: findings from the National Comorbidity Survey. Journal of Affective Disorders 59, 205–215.